SITE003 (CAN) › SITE003-0222

SITE003-0222

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE003 (CAN) · Dr. Okafor
consented 2026-05-23

enrolled

AEs

Serious

Dropout signal

–

Adverse events

Grade 1 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-01-12 (study day 45); relationship: not assessed

mild assessed

Grade 4 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2022-12-13 (study day 15); relationship: not assessed; serious criteria: life-threatening

severe serious assessed

Data queries

No data queries. Open queries would appear here for this patient.